BIOFRONTERA INC (BFRI)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-09
$1.54-1.28%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-09
Intact: The reason to own it still holds.
Biofrontera aims to improve financial results and reduce losses. Revenue is expected to grow from $17 million in 2025 to about $42 million in 2026. The company recently beat earnings but faces a volatile path. Its stock trades cheaply versus peers, offering upside if recovery holds.
Revenue declined sharply from $17.1 million in 2025-Q4 to $10.08 million in 2026-Q1. The company remains loss-making with a net loss of $4.75 million in 2026-Q1. Guidance was cut and analyst confidence fell, signaling ongoing financial struggles.
The market expects about 14% revenue growth next year and values the stock cheaply versus peers. Our fair value of $9.61 implies the market prices in a modest recovery, but recent guidance cuts and earnings misses suggest risks to this view.
Breaks if: Management fails to show consistent progress or issues negative guidance
Focus on enhancing financial results and reducing losses.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story. BFRI is currently loss-making but has shown strong recent financial performance and aims for sustained profitability and cash flow breakeven in 2026.
The market appears to price in a low expectations gap, indicating that BFRI is considered cheap compared to its peers. Despite being in a low fragility tier, the valuation reflects cautious optimism about future performance.
BFRI's fundamentals are mixed, with revenue growth on track due to increased unit volume and price hikes for Ameluz®. However, there is an elevated risk of a next-quarter earnings miss, which could impact sentiment.
The thesis hinges on management's ability to meet profitability targets and the outcomes of upcoming regulatory milestones. Additionally, broader sector performance and economic indicators, such as the jobs report, will influence BFRI's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat indicates improved financial performance. Strong growth in Ameluz unit volume and price increases supports revenue growth. The reason to own it still holds.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Aim to grow revenue through strategic initiatives.
Breaks if: Net loss worsens beyond -$4.75 million in next 4 quarters
Focus on enhancing financial results and reducing losses.
Breaks if: Revenue falls below $17 million in FY26
Aim to grow revenue through strategic initiatives.
Over the next 1 to 3 years, BFRI's success will depend on its execution of growth strategies and external market conditions. Not investment advice.